



(51) International Patent Classification:

A61K 38/05 (2006.01) *A61K 31/353* (2006.01)
A61K 38/06 (2006.01) *A61K 31/407* (2006.01)
A61K 38/07 (2006.01) *A61K 31/426* (2006.01)
A61K 31/145 (2006.01) *A61K 31/69* (2006.01)
A61K 31/198 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2015/031633

(22) International Filing Date:

19 May 2015 (19.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/000,991	20 May 2014 (20.05.2014)	US
62/019,600	1 July 2014 (01.07.2014)	US
62/088,154	5 December 2014 (05.12.2014)	US

(71) Applicant: **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 40 Landsdowne Street, Cambridge, MA 02139 (US).

(72) Inventors: **HUI, Ai-Min**; 1 Payson Street, Lexington, MA 02421 (US). **LABOTKA, Richard**; 536 S. Fourth Avenue, Des Plaines, IL 60016 (US). **GUPTA, Neeraj**; 64 Webster Street, Newton, MA 02465 (US). **VENKATAKRISHNAN, Karthik**; 318 Rindge Avenue Unit 101, Cambridge, MA 02140 (US). **LUI, Guohui**; 65 Gale Road, Belmont, MA 02478 (US).

(74) Agent: **YANG, Lucy, X.**; Honigman Miller Schwartz and Cohn LLP, 350 East Michigan Avenue Suite 300, Kalamazoo, MI 49007 (US).


(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: BORON-CONTAINING PROTEASOME INHIBITORS FOR USE AFTER PRIMARY CANCER THERAPY



(I)

(57) Abstract: The present disclosure relates to methods or dosing regimens comprising a proteasome inhibitor of formula (I), or a pharmaceutically acceptable salt thereof, for treating cancer, or preventing cancer recurrence or progression; wherein ring A, Z¹ and Z² are as defined herein.

